Latest Breaking News On - Biological industries - Page 8 : vimarsana.com

Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent A good 23 percentage points of growth contributed by the coronavirus pandemic Accelerated expansion of production capacities in all regions on track as planned Sartorius Stedim Biotech, a leading partner of the biopharma industry, had an exceptionally strong start to fiscal 2021 and grew substantially in order intake 1, sales revenue and earnings. This was fueled by strong fundamental growth, additional business from vaccine manufacturers, and acquisitions.  Many of our products play an essential role in helping to overcome the pandemic. In addition to a very positive general business performance in the first quarter, we accordingly experienced strong demand for our products and technologies used in the production of vaccines and achieved a sharp increase in sales. The substantial rise in the company s profit margin was also supported by underproportionate development of costs, s

Puerto ricoUnited statesSouth koreaProvence alpes côd azurPetra kirchhoffJoachim kreuzburgAsia pacificWatersep bioseparationsHead of corporate communications investor relationsSartorius stedim biotech groupDanaher corporationStedim biotechSartorius stedim biotechMiddle eastEuropean summer timePerformance indicators